American Association for Cancer Research
Browse
15357163mct130892-sup-fig2.pdf (1.99 MB)

Supplementary Figure 2 from Nuclear Translocation of Hand-1 Acts as a Molecular Switch to Regulate Vascular Radiosensitivity in Medulloblastoma Tumors: The Protein uPAR Is a Cytoplasmic Sequestration Factor for Hand-1

Download (1.99 MB)
journal contribution
posted on 2023-04-03, 14:07 authored by Swapna Asuthkar, Venkateswara Rao Gogineni, Jasti S. Rao, Kiran Kumar Velpula

PDF file - 2038K, Supplementary Fig.2. Hand-1-mediated negative regulation of HIF-1A.

History

ARTICLE ABSTRACT

Urokinase-type plasminogen activator receptor (uPAR) is overexpressed in the tumor–stromal invasive microenvironment in many human cancers, including medulloblastoma. The role of uPAR in tumor progression and angiogenesis has been well characterized. Previously, in medulloblastoma cells, we showed that ionizing radiation (IR)–induced uPAR is a potent activator of cancer stem cell (CSC)–like properties and is associated with various transcription factors that are involved during embryonic development and cancer. In the present study, we show that uPAR protein acts as a cytoplasmic sequestration factor for a novel basic helix-loop-helix transcription factor, Hand-1. The Hand-1 protein plays an essential role in the differentiation of trophoblast giant cells and cardiac morphogenesis, and yet its precise cellular function and its contribution to cancer remain mostly unknown. We also observed that the Hand-1 protein is upregulated in uPAR short hairpin RNA–treated medulloblastoma cells and accompanies sustained cell growth and angiogenesis. Furthermore, IR-induced uPAR overexpression negatively regulates Hand-1 activity and results in the stabilization of angiogenesis-promoting molecules, including hypoxia-inducible factor-1α. Finally, uPAR overexpression and its association with Hand-1 after IR treatment indicate that uPAR is capable of regulating Hand-1 and that uPAR has a role in the process of IR-induced tumor angiogenesis. Mol Cancer Ther; 13(5); 1309–22. ©2014 AACR.

Usage metrics

    Molecular Cancer Therapeutics

    Licence

    Exports

    RefWorks
    BibTeX
    Ref. manager
    Endnote
    DataCite
    NLM
    DC